S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 974-979

  Kim, W T ^a   Kim, J ^b   Yan, C ^a   Jeong, P ^a   Choi, S Y ^c   Lee, O J ^c   Chae, Y B ^d   Yun, S J ^a   Lee, S C ^a   Kim, W J ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Chungbuk National University   (South Korea)

^d Cheongju St Mary's Hospital   (South Korea)

Author keywords

drug resistance; epidermal growth factor; receptor; urinary bladder; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CALGRANULIN B; CISPLATIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

AGED; APOPTOSIS; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE; TUMOR CELL LINE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALGRANULIN B; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84906069616     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu037     Document Type: Article

References (22)

1. Sternberg, C.N., The treatment of advanced bladder cancer. Ann Oncol 6 (1995), 113–126.
2. Rosenberg, J.E., Carroll, P.R., Small, E.J., Update on chemotherapy for advanced bladder cancer. J Urol 174 (2005), 14–20.
3. Saxman, S.B., Propert, K.J., Einhorn, L.H., Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997), 2564–2569.
4. von der Maase, H., Sengelov, L., Roberts, J.T., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005), 4602–4608.
5. Kim, W.J., Kim, S.K., Jeong, P., A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 17 (2011), 478–485.
6. Bellmunt, J., Paz-Ares, L., Cuello, M., Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18 (2007), 522–528.
7. Bajorin, D.F., Ostrovnaya, I., Iasonos, A., et al. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. J Clin Oncol, 25, 2007 18s, suppl; abstr 5055).
8. Shariat, S.F., Kim, J.H., Andrews, B., Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92 (2001), 2985–2992.
9. Andrews, B., Shariat, S.F., Kim, J.H., et al. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167 (2002), 1475–1481.
10. Shariat, S.F., Kim, J., Nguyen, C., et al. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology 61 (2003), 359–364.
11. Mitra, A.P., Pagliarulo, V., Yang, D., Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 27 (2009), 3929–3937.
12. Yong, H.Y., Moon, A., Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res 30 (2007), 75–81.
13. Hermani, A., De Servi, B., Medunjanin, S., et al. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312 (2006), 184–197.
14. Stulik, J., Osterreicher, J., Koupilova, K., The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis 20 (1999), 1047–1054.
15. Rafii, S., Lyden, D., S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 8 (2006), 1321–1323.
16. Yang, W.S., Moon, H.G., Kim, H.S., Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. J Proteome Res 11 (2012), 1078–1088.
17. Acharyya, S., Oskarsson, T., Vanharanta, S., A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150 (2012), 165–178.
18. Nicholson, R.I., Gee, J.M., Harper, M.E., EGFR and cancer prognosis. Eur J Cancer 37 (2001), S9–S15.
19. Bellmunt, J., Hussain, M., Dinney, C.P., Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46 (2003), S85–S104.
20. Bland, J.M., Altman, D.G., Transformations, means, and confidence intervals. BMJ, 312, 1996, 1079.
21. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 (2004), 1828–1837.
22. Paik, S., Shak, S., Tang, G., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004), 2817–2826.